AccScience Publishing / GTM / Volume 2 / Issue 2 / DOI: 10.36922/gtm.0403
Submit to GTM
Cite this article
88
Download
831
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW

Utility of cardiac biomarkers and biosensors for diagnosis of acute myocardial infarction

Rupali Shinde1 ,  Isha Juwarwala1 ,  Vishal Modi2 ,  Chandni V. Chandarana1*
Show Less
1 Department of Quality Assurance, SSR College of Pharmacy, Sayli, Silvassa, U.T. of Dadra Nagar Haveli, 396230, India
2 Department of Pharmaceutical Chemistry, Swaminarayan Sanskar Pharmacy College, Zundal, Gandhinagar, Gujarat, 382421, India
Global Translational Medicine 2023, 2(2), 0403 https://doi.org/10.36922/gtm.0403
Submitted: 6 April 2023 | Accepted: 16 June 2023 | Published: 28 June 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Acute myocardial infarction (AMI) is the most prevalent condition that results in sickness and death worldwide. An early and accurate diagnosis of AMI is critical for prompt and appropriate treatment. Cardiac biomarkers, including myoglobin, creatinine phosphokinase (CK), and cardiac troponins, have been widely used for AMI diagnosis. More recently, new biomarkers such as heart-type fatty acid-binding protein and matrix metalloproteinases have shown promise in improving AMI diagnosis. At present, cardiac biomarkers and biosensors are used in the diagnosis and prognosis of AMI. This review article gives information on cardiac biomarkers specific to AMI and its diagnostic methods. These biomarkers have several advantages, including their high specificity for cardiac injury and their sensitivity to even small extent of cardiac damage. In addition, cardiac biomarkers can be used to assess the severity of AMI and predict the risk of complications or mortality. Recently, biosensors that can detect cardiac biomarkers in real time have been developed, allowing for an earlier and more accurate diagnosis of AMI. The utility of cardiac biomarkers and biosensors in the diagnosis of AMI underscores the importance of early and accurate diagnosis and treatment of this life-threatening condition.

Keywords
Acute myocardial infraction
Cardiac biomarker
Colorimetric
Electrochemical method
Aptamer
Funding
None
References
  1. Ojha N, Dhamoon AS, 2022, Myocardial infarction. In: StatPearls. Treasure Island, FL: StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/nbk537076 [Last accessed on 2023 Jun 06].

 

  1. Savonnet M, Rolland T, Cubizolles M, et al., 2021, Recent advances in cardiac biomarkers detection: From commercial devices to emerging technologies. J Pharm Biomed Anal, 194: 113777. https://doi.org/10.1016/j.jpba.2020.113777

 

  1. Ahammad AJS, Choi YH, Koh K, et al., 2011, Electrochemical detection of cardiac biomarker troponin I at gold nanoparticle-modified ITO electrode by using open circuit potential. Int J Electrochem Sci, 6: 1906–1916.

 

  1. Mahajan VS, Jarolim P, 2011, How to interpret elevated cardiac troponin levels. Circulation, 124: 2350–2354. https://doi.org/10.1161/circulationaha.111.023697

 

  1. Rashid S, Malik A, Khurshid R, et al., 2019, The diagnostic value of biochemical cardiac markers in acute myocardial infarction. In: Myocardial Infarction. London, UK: IntechOpen. https://doi.org/10.5772/intechopen.76150

 

  1. Falahati A, Sharkey SW, Christensen D, et al., 1999, Implementation of serum cardiac troponin I as marker for detection of acute myocardial infarction. Am Heart J, 137: 332–337. https://doi.org/10.1053/hj.1999.v137.92412

 

  1. Garg P, Morris P, Fazlanie AL, et al., 2017, Cardiac biomarkers of acute coronary syndrome: From history to high-sensitivity cardiac troponin. Intern Emerg Med, 12: 147–155. https://doi.org/10.1007/s11739-017-1612-1

 

  1. Van Nieuwenhoven FA, Kleine AH, Wodzig KH, et al., 1995, Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein. Circulation, 92: 2848–2854. https://doi.org/10.1161/01.cir.92.10.2848

 

  1. Lewandrowski K, Chen A, Januzzi J, 2002, Cardiac markers for myocardial infarction. A brief review. Am J Clin Pathol, 118: S93–S99. https://doi.org/10.1309/3ek7-yvv9-228c-e1xt

 

  1. Tilea I, Varga A, Serban RC, 2021, Past, present, and future of blood biomarkers for the diagnosis of acute myocardial infarction-promises and challenges. Diagnostics (Basel), 11: 881. https://doi.org/10.3390/diagnostics11050881

 

  1. Reyes-Retana JA, Duque-Ossa LC, 2021, Acute myocardial infarction biosensor: A review from bottom up. Curr Probl Cardiol, 46: 100739. https://doi.org/10.1016/j.cpcardiol.2020.100739

 

  1. High-sensitivity Troponin Test: Normal and High Levels. Available from: https://www.medicinenet.com/high_sensitivity_troponin_test_ranges_and_values/article.htm [Last accessed on 2023 Jun 06].

 

  1. Vasile VC, Jaffe AS, 2017, High-sensitivity cardiac troponin for the diagnosis of patients with acute coronary syndromes. Curr Cardiol Rep, 19: 92. https://doi.org/1010.1007/s11886-017-0904-4

 

  1. Collinson PO, Boa FG, Gaze DC, 2001, Measurement of cardiac troponins. Ann Clin Biochem, 38: 423–449. https://doi.org/10.1177/000456320103800501

 

  1. Shave R, Dawson E, Whyte G, et al., 2002, The cardiospecificity of the third-generation cTnT assay after exercise-induced muscle damage. Med Sci Sports Exerc, 34: 651–654. https://doi.org/10.1097/00005768-200204000-00014

 

  1. Chan D, Ng LL, 2010, Biomarkers in acute myocardial infarction. BMC Med, 8: 34. https://doi.org/10.1186/1741-7015-8-34

 

  1. Hazen SL, Heinecke JW, 1997, 3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest, 99: 2075–2081. https://doi.org/10.1172/JCI119379

 

  1. Thukkani AK, McHowat J, Hsu FF, et al., 2003, Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation, 108: 3128–3133. https://doi.org/10.1161/01.cir.0000104564.01539.6a

 

  1. Beckmann JS, Ye YZ, Anderson PG, et al., 1994, Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler, 375: 81–88. https://doi.org/10.1515/bchm3.1994.375.2.81

 

  1. Hazell LJ, Baernthaler G, Stocker R, 2001, Correlation between intima-to-media ratio, apolipoprotein B-100, myeloperoxidase, and hypochlorite-oxidized proteins in human atherosclerosis. Free Radic Biol Med, 31: 1254–1262. https://doi.org/10.1016/s0891-5849(01)00717-1

 

  1. Kutter D, Devaquet P, Vanderstocken G, et al., 2000, Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? Acta Haematol, 104: 10–15. https://doi.org/10.1159/000041062

 

  1. Nikpoor B, Turecki G, Fournier C, et al., 2001, A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J, 142: 336–339. https://doi.org/10.1067/mhj.2001.116769

 

  1. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al., 2003, A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients S-172. Kidney Int Suppl, 63: S172–S176. https://doi.org/10.1046/j.1523-1755.63.s84.32.x

 

  1. Brennan ML, Penn MS, Van Lente F, et al., 2003, Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med, 17: 1595–1604. https://doi.org/10.1056/NEJMoa035003

 

  1. Baldus S, Heeschen C, Meinertz T, et al., 2003, Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 108: 1440–1445. https://doi.org/10.1161/01.CIR.0000090690.67322.51

 

  1. Wang W, Schulze CJ, Suarez-Pinzon WL, et al., 2002, Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation, 106: 1543–1549. https://doi.org/10.1161/01.cir.0000028818.33488.7b

 

  1. Kwan JA, Schulze CJ, Wang W, et al., 2004, Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADPribose) polymerase (PARP) in vitro. FASEB J, 18: 690–692. https://doi.org/10.1096/fj.02-1202fje

 

  1. Morrow DA, Braunwald E, 2003, Future of biomarkers in acute coronary syndromes: Moving toward a multimarker strategy. Circulation, 108: 250–252. https://doi.org/10.1161/01.cir.0000078080.37974.d2

 

  1. Lund J, Qin QP, Ilva T, et al., 2003, Circulating pregnancyassociated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation, 108: 1924–1926. https://doi.org/10.1161/01.cir.0000096054.18485.07

 

  1. Bayes-Genis A, Conover CA, Schwartz RS, 2000, The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res, 86: 125–130. https://doi.org/10.1161/01.res.86.2.125

 

  1. Nishikimi T, Asakawa H, Iida H, et al., 2004, Different secretion patterns of two molecular forms of cardiac adrenomedullin in pressure-and volume-overloaded human heart failure. J Card Fail, 10: 321–327. https://doi.org/10.1016/j.cardfail.2003.12.002

 

  1. Miyao Y, Nishikimi T, Goto Y, et al., 1998, Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart, 79: 39–44. https://doi.org/10.1136/hrt.79.1.39

 

  1. Mohan G, Kaur R, Singh T, 2017, Cardiac biomarkers in acute coronary syndrome. Curr Trends Diagn Treat, 1: 80–88. https://doi.org/10.5005/jp-journals-10055-0019

 

  1. Duma RJ, Siegel AL, 1965, Serum creatinine phosphokinase in acute myocardial infarction: Diagnostic value. Arch Intern Med, 115: 443–451. https://doi.org/10.1001/archinte.1965.03860160069011

 

  1. Itoi K, Jiang YQ, Iwasakiz Y, et al., 2004, Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol, 16: 348–355. https://doi.org/10.1111/j.0953-8194.2004.01172.x

 

  1. Gheorghiade M, Gattis WA, O’Connor CM, et al., 2004, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA, 291: 1963–1971. https://doi.org.10.1001/jama.291.16.1963

 

  1. Abraham WT, Shamshirsaz AA, McFann K, et al., 2006, Aquaretic effect of lixivaptan, an oral, non-peptide, selective v2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol, 47: 1615–1621. https://doi.org/10.1016/j.jacc.2005.11.071

 

  1. Rezar R, Jirak P, Gschwandtner M, et al., 2020, Hearttype fatty acid-binding protein (H-FABP) and its role as a biomarker in heart failure: What do we know so far? J Clin Med, 9: 164. https://doi.org/10.3390/jcm9010164

 

  1. Atay E, Guzel M, Amanvermez R, et al., 2019, Role of Gal-3 and H-FABP in the early diagnosis of acute coronary syndrome. Bratisl Lek Listy, 120: 124–130. https://doi.org/10.4149/bll_2019_020

 

  1. Levin ER, Gardner DG, Samson WK, 1998, Natriureticpeptides. N Engl J Med, 339: 321–328. https://doi.org/10.1056/NEJM199807303390507

 

  1. De Ames JA, Morrow DA, Bentley JH, et al., 2001, The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med, 345: 1014–1021. https://doi.org/10.1056/nejmoa011053

 

  1. Vasile VC, Babuin L, Giannitsis E, et al., 2008, Relationship of MRI-determined infarct size and cTnI measurements in patients with ST-elevation myocardial infarction. Clin Chem, 54: 617–619. https://doi.org/10.1373/clinchem.2007.095604

 

  1. Richards AM, Nicholls MG, Yandle TG, et al., 1998, Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation, 97: 1921–1929. https://doi.org/10.1161/01.cir.97.19.1921

 

  1. Squire IB, O’Brien RJ, Demme B, et al., 2004, N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci, 107: 309–316. https://doi.org/10.1042/CS20040087

 

  1. Morgenthaler NG, Struck J, Thomas B, et al., 2004, Immunoluminometric assay for the midregion of proatrial natriuretic peptide in human plasma. Clin Chem, 50: 234–236. https://doi.org/10.1373/clinchem.2003.021204

 

  1. Khan SQ, Dhillon O, Kelly D, et al., 2008, Plasma N-terminal B-type natriuretic Peptide as an indicator of long-term survival after acute myocardial infarction: Comparison with plasma midregional pro-atrial natriuretic peptide. The LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol, 51: 1857–1864. https://doi.org/10.1016/j.jacc.2008.01.041

 

  1. Ho JE, Mahajan A, Chen MH, et al., 2012, Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem, 58: 1582–1591. https://doi.org/10.1373/clinchem.2012.190322

 

  1. Schopfer DW, Ku IA, Regan M, et al., 2014, Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study). Am Heart J, 167: 186–192.e1. https://doi.org/10.1016/j.ahj.2013.09.013

 

  1. Zhang S, Dai D, Wang X, et al., 2016, Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: A meta-analysis. BMC Cardiovasc Disord, 16: 82. https://doi.org/10.1186/s12872-016-0250-2

 

  1. Xie S, Lu L, Liu L, 2019, Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: A meta-analysis of prospective studies. Clin Cardiol, 42: 513–523. https://doi.org/10.1002/clc.23159

 

  1. Daniels LB, Clopton P, Laughlin GA, et al., 2011, Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: The Rancho Bernardo Study. Circulation, 123: 2101–2110. https://doi.org/10.1161/circulationaha.110.979740

 

  1. Bodde MC, Hermans MPJ, van der Laarse A, et al., 2019, Growth differentiation factor-15 levels at admission provide incremental prognostic information on all-cause long-term mortality in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Cardiol Ther, 8: 29–41. https://doi.org/10.1007/s40119-019-0127-4

 

  1. Wang XY, Zhang F, Zhang C, et al., 2020, The biomarkers for acute myocardial infarction and heart failure. Biomed Res Int, 2020: 2018035. https://doi.org/10.1155/2020/2018035

 

  1. Sanada S, Hakuno D, Higgins LJ, et al., 2007, IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest, 117: 1538–1549. https://doi.org/10.1172/JCI30634

 

  1. Seki K, Sanada S, Kudinova AY, et al., 2009, Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail, 2: 684–691. https://doi.org/10.1161/circheartfailure.109.873240

 

  1. Diez J, 2008, Serum soluble ST2 as a biochemical marker of acute heart failure. Future areas of research. J Am Coll Cardiol, 52: 1466–1467. https://doi.org/10.1016/j.jacc.2008.07.045

 

  1. Zhou L, Liu Y, Lu Y, et al., 2022, Recent advances in the immunoassays based on nanozymes. Biosensors (Basel), 12: 1119. https://doi.org/10.3390/bios12121119

 

  1. Yang J, Wang X, Sun Y, et al., 2023, Recent advances in colorimetric sensors based on gold nanoparticles for pathogen detection. Biosensors (Basel), 13: 29. https://doi.org/10.3390/bios13010029

 

  1. Choi DH, Lee SK, Oh YK, et al., 2010, A dual gold nanoparticle conjugate-based lateral flow assay (LFA) method for the analysis of troponin I. Biosens Bioelectron, 25: 1999–2002. https://doi.org/10.1016/j.bios.2010.01.019

 

  1. Benjamin SR, Santos LKB, Silva JEG, et al., 2023, Electrochemical Immunosensors and Biomimetic Sensors for the Detection of the Myocardial Infarction Biomarkers. United States: Crimson Publishers.

 

  1. Liu J, Zhang L, Wang Y, et al., 2014, An improved portable biosensing system based on enzymatic chemiluminescence and magnetic immunoassay for biological compound detection. Measurement, 47: 200–206. https://doi.org/10.1016/j.measurement.2013.08.057

 

  1. Aslan K, Grell TAJ, 2011, Rapid and sensitive detection of troponin I in human whole blood samples by using silver nanoparticle films and microwave heating. Clin Chem, 57: 746–752. https://doi.org/10.1373/clinchem.2010.159889

 

  1. Qureshi A, Gurbuz Y, Niazi JH, 2012, Biosensors for cardiac biomarkers detection: A review. Sens Actuators B Chem, 171–172: 62–76. https://doi.org/10.1016/j.snb.2012.05.077

 

  1. Masson JF, Battaglia TM, Khairallah P, et al., 2007, Quantitative measurement of cardiac markers in undiluted serum. Anal Chem, 79: 612–619. https://doi.org/10.1021/ac061089f

 

  1. Plowman TE, Durstchi JD, Wang HK, et al., 1999, Multipleanalyte fluoroimmunoassay using an integrated optical waveguide sensor. Anal Chem, 71: 4344–4352. https://doi.org/10.1021/ac990183b

 

  1. Wolf M, Juncker D, Michel B, et al., 2004, Simultaneous detection of C-reactive protein and other cardiac markers in human plasma using micromosaic immunoassays and self-regulating microfluidic networks. Biosens Bioelectron, 19: 1193–1202. https://doi.org/10.1016/j.bios.2003.11.003
Conflict of interest
The authors declare no conflicts of interest.
Share
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept